CD274 and pancreatic ductal adenocarcinoma: Twenty-eight treatment naïve patients with pancreatic ductal adenocarcinoma diagnosed through EUS-FNB were subjected to IHC tests in order to assess adequacy for MMR status and PD-L1 expression testing.